Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab after rituximab in IgA2 anti-dsDNA positive lupus
ISRCTN76569516Phase 3Recruiting
- Sponsor
- University College London
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial in systemic lupus erythematosus (SLE) comparing Belimumab after rituximab with Placebo after rituximab (2 arms). Primary endpoint: Modified Major Clinical Response at 52 weeks. Started Nov 2026; status: recruiting.
02
Drugs
belimumabrituximab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ISRCTN76569516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN76569516.